Search results for " Cardiovascular disease"

showing 10 items of 179 documents

Carbohydrate quality changes and concurrent changes in cardiovascular risk factors: a longitudinal analysis in the PREDIMED-Plus randomized trial.

2020

[Background]: Overall quality of dietary carbohydrate intake rather than total carbohydrate intake may determine the risk of cardiovascular disease (CVD).

PREDIMED-Plus carbohydrate carbohydrate quality index cardiovascular disease fiber glycemic index obesity randomized controlled trialsMaleobesity030309 nutrition & dieteticsMedicine (miscellaneous)030204 cardiovascular system & hematologyOverweightchemistry.chemical_compound0302 clinical medicinecardiovascular diseaseRisk FactorsSurveys and QuestionnairesGlycemic indexLongitudinal StudiesProspective Studies2. Zero hunger0303 health sciencesNutrition and DieteticsMiddle AgedCardiovascular disease3. Good healthGlycemic indexCardiovascular Diseasesrandomized controlled trialsRandomized controlled trialsFemalemedicine.symptomfibermedicine.medical_specialtyWaistCarbohydrates03 medical and health sciencesInternal medicinemedicineDietary CarbohydratesHumansFiberObesityAgedCarbohydrate quality indexTriglyceridebusiness.industryPREDIMED-PlusOverweightmedicine.diseaseObesityDietBlood pressurechemistrycarbohydratecarbohydrate quality indexglycemic indexGlycated hemoglobinMetabolic syndromebusinessEnergy Intake
researchProduct

Moderate alcohol use and health: a consensus document

2013

Abstract Aims The aim of this consensus paper is to review the available evidence on the association between moderate alcohol use, health and disease and to provide a working document to the scientific and health professional communities. Data synthesis In healthy adults and in the elderly, spontaneous consumption of alcoholic beverages within 30 g ethanol/d for men and 15 g/d for women is to be considered acceptable and do not deserve intervention by the primary care physician or the health professional in charge. Patients with increased risk for specific diseases, for example, women with familiar history of breast cancer, or subjects with familiar history of early cardiovascular disease, …

Polyphenolmedicine.medical_specialtyEndocrinology Diabetes and MetabolismMEDLINEMedicine (miscellaneous)Cognitive declineDiseaseDiabetealcohol; cancer; cardiovascular disease; cognitive decline; diabetes; metabolic syndrome; overall mortality; polyphenols; preventionALCOHOLIC LIVER DISEASEBreast cancerDiabetes mellitusIntervention (counseling)medicineOverall mortalityCognitive declinePsychiatrypolyphenolsCancerNutrition and Dieteticsdiabetesbusiness.industryPreventionPrimary care physicianmedicine.diseaseModerationCardiovascular diseaseMetabolic syndromeSettore MED/11 - Malattie Dell'Apparato CardiovascolareHEALTHCardiology and Cardiovascular MedicinebusinessAlcohol; Cardiovascular disease; Cancer; Prevention; Polyphenols; Diabetes; Metabolic syndrome; Cognitive decline; Overall mortalityAlcohol
researchProduct

Editor's Choice - Frailty and the management of patients with acute cardiovascular disease:A position paper from the Acute Cardiovascular Care Associ…

2018

Frailty is increasingly seen among patients with acute cardiovascular disease. A combination of an ageing population, improved disease survival, treatable long-term conditions as well as a greater recognition of the syndrome has accelerated the prevalence of frailty in the modern world. Yet, this has not been matched by an expansion of research. National and international bodies have identified acute cardiovascular disease in the frail as a priority area for care and an entity that requires careful clinical decisions, but there remains a paucity of guidance on treatment efficacy and safety, and how to manage this complex group. This position paper from the Acute Cardiovascular Care Associa…

Population ageingmedicine.medical_specialtyCritical Careheart failureCardiovascular careDisease030204 cardiovascular system & hematologyCritical Care and Intensive Care Medicine03 medical and health sciences0302 clinical medicineacute cardiovascular caremedicineHumansacute coronary syndromesatrial fibrillation030212 general & internal medicineIntensive care medicineFrailtybusiness.industryAtrial fibrillationGeneral Medicinemedicine.diseaseTreatment efficacyAcute cardiovascular diseasecritical careTreatment OutcomeCardiovascular DiseasesHeart failureAcute DiseasePosition paperCardiology and Cardiovascular Medicinebusiness
researchProduct

The appropriate and justified use of medical radiation in cardiovascular imaging: a position document of the ESC Associations of Cardiovascular Imagi…

2014

The benefits of cardiac imaging are immense, and modern medicine requires the extensive and versatile use of a variety of cardiac imaging techniques. Cardiologists are responsible for a large part of the radiation exposures every person gets per year from all medical sources. Therefore, they have a particular responsibility to avoid unjustified and non-optimized use of radiation, but sometimes are imperfectly aware of the radiological dose of the examination they prescribe or practice. This position paper aims to summarize the current knowledge on radiation effective doses (and risks) related to cardiac imaging procedures. We have reviewed the literature on radiation doses, which can range …

Prenatal Diagnosimedicine.medical_treatmentScintigraphyImagingPregnancyRisk FactorsPrenatal DiagnosisCancer; Cardiovascular disease; Imaging; Radiation; Radiological protection; Risk; Cardiac Imaging Techniques; Cardiology; Child; Female; Heart Diseases; Humans; Informed Consent; Occupational Exposure; Pregnancy; Pregnancy Complications; Prenatal Diagnosis; Radiation Injuries; Radiation Protection; Risk Factors; Tomography X-Ray Computed; Unnecessary Procedures; Radiation Dosage; Cardiology and Cardiovascular MedicineRadiation InjurieChildTomographyRadiological protectionCardiac imagingCancerRadiationInformed Consentmedicine.diagnostic_testCardiovascular diseasePregnancy ComplicationX-Ray ComputedHeart DiseaseFemaleRadiologyCardiology and Cardiovascular MedicineHumanUnnecessary ProcedureRiskmedicine.medical_specialtyModern medicineHeart DiseasesCardiologyUnnecessary ProceduresRadiation DosageMyocardial perfusion imagingRadiation ProtectionOccupational ExposuremedicineMedical imagingHumansMedical physicsRadiation Injuriesta3126Cardiac Imaging Techniquebusiness.industryRisk FactorPercutaneous coronary interventionMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREta3121Pregnancy ComplicationsCardiac Imaging TechniquesCardiac Imaging TechniquesRadiation protectionTomography X-Ray Computedbusiness
researchProduct

Catalyzing transcriptomics research in cardiovascular disease: The CardioRNA COST action CA17129

2019

WOS: 000474931400001

Project Report0301 basic medicinemedicine.medical_specialtyBiochemistry & Molecular BiologyKnowledge managementlcsh:QH426-470BIOMARKERSbest practices and guidelines; cardiovascular disease; personalized medicine; transcriptomics; translational researchContext (language use)Translational researchDisease030204 cardiovascular system & hematologyBiologyBiochemistryLONG NONCODING RNAS03 medical and health sciencestranscriptomics0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemCIRCULATING MICRORNASTARGETScardiovascular diseaseGeneticsmedicineCost actionSet (psychology)Molecular BiologyComputingMilieux_MISCELLANEOUSGenetics & HeredityScience & Technologybusiness.industryCardiovascular system -- DiseasesPublic healthMedicine -- Research -- International cooperationpersonalized medicine3. Good healthlcsh:Genetics030104 developmental biologyAction (philosophy)PERSPECTIVEStranslational researchPersonalized medicineTranslational research biomedicalbest practices and guidelinesbusinessTranscriptomeLife Sciences & Biomedicine
researchProduct

Managing the Systemic Impact of Periodontitis

2022

Periodontitis is a microbially driven host-mediated disease that leads to loss of periodontal attachment and bone. It is associated with elevation of systemic inflammatory markers and with the presence of systemic co-morbidities. Furthermore, periodontal treatment leads to a 24–48 h-long acute local and systemic inflammatory response. This systemic response might increase the burden of patients with compromised medical history and/or uncontrolled systemic diseases. The correlation between periodontitis and systemic diseases, the impact of periodontitis on the quality of life and public health, the effects of periodontal treatment on systemic health and disease, and the available methods to …

Quality of lifeInflammationPublic healthGeneral MedicineMetabolic syndromePregnancy outcomebiomarkers cardiovascular diseases diabetes mellitus inflammation metabolic syndrome periodontitis pregnancy outcome psoriasis public health quality of lifeCardiovascular diseasesDiabetes mellitusQuality of LifePsoriasisHumansPeriodontitisBiomarkers
researchProduct

Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases - A position paper from the Internationa…

2021

Inflammation is a marker of arterial disease stemming from cholesterol-dependent to -independent molecular mechanisms. In recent years, the role of inflammation in atherogenesis has been underpinned by pharmacological approaches targeting systemic inflammation that have led to a significant reduction in cardiovascular disease (CVD) risk. Although the use of nutraceuticals to prevent CVD has largely focused on lipid-lowering (e.g, red-yeast rice and omega-3 fatty acids), there is growing interest and need, especially now in the time of coronavirus pandemic, in the use of nutraceuticals to reduce inflammatory markers, and potentially the inflammatory CVD burden, however, there is still not en…

RMArterial diseaseAnti-Inflammatory AgentsInflammationDiseaseC-reactive protein ; cardiovascular disease ; inflammation ; nutraceuticals ; omega-3 ; position paper ; red-yeast rice030204 cardiovascular system & hematologyBioinformaticsSystemic inflammationC-reactive protein03 medical and health sciences0302 clinical medicineNutraceuticalMedicineHumansPosition paper030212 general & internal medicineUncategorizedOmega-3InflammationbiologyC-reactive protein; Cardiovascular disease; Inflammation; Nutraceuticals; Omega-3; Position paper; Red-yeast rice; Anti-Inflammatory Agents; Biomarkers; Cardiovascular Diseases; Humans; Inflammation; Lipids; Dietary SupplementsVascular inflammationbusiness.industryC-reactive proteinC-reactive protein Cardiovascular disease Inflammation Nutraceuticals Omega-3 Position paper Red-yeast rice Anti-Inflammatory Agents Biomarkers Cardiovascular Diseases Humans Inflammation Lipids Dietary SupplementsCardiovascular diseaseRed-yeast riceLipidsCardiovascular DiseasesDietary Supplementsbiology.proteinPosition paperNutraceuticalsNutraceuticalmedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersProgress in cardiovascular diseases
researchProduct

The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Car…

2021

A nationwide cross-sectional study, LIPIDOGRAM2015, was carried out in Poland in the years 2015 and 2016. A total of 438 primary care physicians enrolled 13,724 adult patients that sought medical care in primary health care practices. The prevalence of hypertension, diabetes mellitus, dyslipidaemia, and CVD were similar in urban and rural areas (49.5 vs. 49.4%; 13.7 vs. 13.1%; 84.2 vs. 85.2%; 14.4 vs. 14.2%, respectively). The prevalence of obesity (32.3 vs. 37.5%, p p p p = 0.04) and non-HDL-C (147 vs. 148 mg/dL, p = 0.03) were slightly higher in rural populations. Altogether, 14.3% of patients with CVD from urban areas and 11.3% from rural areas reached LDL p = 0.04). There were no import…

RMWaistDiseasePrimary careArticleDiabetes mellitusmedicinerisk factorsUrbanRuralAbdominal obesityPrimary health carebusiness.industryRprimary health care; cardiovascular diseases; risk factors; urban; rural; Poland1103 Clinical SciencesGeneral Medicinemedicine.diseaseObesitycardiovascular diseasesprimary health careCardiovascular diseasesBlood pressureRisk factorsMedicineruralPolandRural areamedicine.symptombusinessurbanDemography
researchProduct

Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation

2015

Left ventricular hypertrophy (LVH) is significantly related to adverse clinical outcomes in patients at high risk of cardiovascular events. In patients with atrial fibrillation (AF), data on LVH, that is, prevalence and determinants, are inconsistent mainly because of different definitions and heterogeneity of study populations. We determined echocardiographic-based LVH prevalence and clinical factors independently associated with its development in a prospective cohort of patients with non-valvular (NV) AF. From the "Atrial Fibrillation Registry for Ankle-brachial Index Prevalence Assessment: Collaborative Italian Study" (ARAPACIS) population, 1,184 patients with NVAF (mean age 72 ± 11 yea…

RegistrieMaleCross-sectional studyMyocardial InfarctionLongitudinal StudieLeft ventricular hypertrophyCohort Studiesnon-valvular atrial fibrillationAtrial Fibrillation80 and overPrevalenceechocardiographyMyocardial infarctionLongitudinal StudiesProspective StudiesRegistriesProspective cohort studyUltrasonographyAged 80 and overeducation.field_of_studyMedicine (all)Atrial fibrillationDiabetes MellituMiddle AgedLeft Ventricularleft ventricular hypertrophyItalyHypertensionCardiologyAge Distribution; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension; Hypertrophy Left Ventricular; Italy; Logistic Models; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Prevalence; Prospective Studies; Ultrasonography; Registries; Cardiology and Cardiovascular Medicine; Medicine (all)Hypertrophy Left VentricularFemaleCardiology and Cardiovascular MedicineHumanmedicine.medical_specialtyLogistic ModelPopulationConcentric hypertrophySocio-culturalenon-valvular atrial fibrillation left ventricular hypertrophy echocardiography cardiovascular diseasesPeripheral Arterial DiseaseAge DistributionInternal medicinemedicineDiabetes MellitusHumansAnkle Brachial Indexcardiovascular diseaseseducationAgedCross-Sectional Studiebusiness.industryAge Distribution; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension; Hypertrophy Left Ventricular; Italy; Logistic Models; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Prevalence; Prospective Studies; Ultrasonography; Registries; Cardiology and Cardiovascular MedicineOdds ratioHypertrophymedicine.diseasecardiovascular diseasesProspective StudieCross-Sectional StudiesLogistic ModelsCohort StudiebusinessAge Distribution; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension; Hypertrophy Left Ventricular; Italy; Logistic Models; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Prevalence; Prospective Studies; Ultrasonography; Registries
researchProduct

Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2)

2011

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a calcium-independent phospholipase A2 that circulates in plasma in association with lipoprotein particles, whereas in atherosclerotic plaques it is co-localized with macrophages. Lp-PLA2 generates two proinflammatory mediators, lysophosphatidylcholine and oxidized nonesterified fatty acids, which play a role in the development of atherosclerotic lesions and formation of a necrotic core, leading to more vulnerable plaques. Epidemiologic studies demonstrate that increased circulating levels of Lp-PLA2 predict an increased risk of myocardial infarction, stroke and cardiovascular mortality. Furthermore, histologic examination of diseased hum…

RiskPathologymedicine.medical_specialtycoronary-artery-diseasecardiovascular-diseasePharmacologyatherosclerotic plaqueProinflammatory cytokinechemistry.chemical_compoundPhospholipase A2cardiovascular diseaseDarapladibOximesDrug DiscoveryHyperlipidemiamedicineHumansMyocardial infarctionPharmacologyClinical Trials as Topicbiologylow-density-lipoproteinLipoprotein-associated phospholipase A2risk-assessmentCardiovascular AgentsAtherosclerosismedicine.diseaselp-pla2heart-diseaselipoproteinsLysophosphatidylcholinechemistryCardiovascular DiseasesinflammationBenzaldehydes1-Alkyl-2-acetylglycerophosphocholine Esterasebiology.proteindarapladibrheumatoid-arthritislipids (amino acids peptides and proteins)atherosclerosisfactor-acetylhydrolase activityAtherosclerosis Cardiovascular disease Darapladib Inflammation Lipoproteins Lp-PLA2.platelet-activating-factorsecondary preventionLipoprotein
researchProduct